MUC1 and colorectal carcinoma: Similarly, a study by Shou et al. in 50 relapsed patients with stage III or stage IV CRC patients identified a novel six-gene assay (CEA, EpCAM, Cytokeratin 19 (CK19), Mucin 1(MUC1), EGFR and tyrosine-protein kinase Met (C-Met markers) in CTC indicating the role of these markers as effective predictors of progression-free survival in CRC [162].